Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female Mice

被引:71
作者
Kaneb, Hannah M. [1 ,2 ]
Sharp, Paul S. [1 ,3 ]
Rahmani-Kondori, Nazanin [1 ,2 ]
Wells, Dominic J. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Wolfson Neurosci Labs, Fac Med, London, England
[2] Univ London Royal Vet Coll, Dept Vet Basic Sci, London, England
[3] Univ Sheffield, Acad Neurol Unit, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England
基金
英国医学研究理事会;
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; ACTIVATED PROTEIN-KINASE; MOTOR UNIT LOSS; DISEASE PROGRESSION; HUNTINGTONS-DISEASE; ENDOTHELIAL-CELLS; FAMILIAL ALS; MECHANISM; MITOCHONDRIA; DYSFUNCTION;
D O I
10.1371/journal.pone.0024189
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Amyotrophic Lateral Sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motor neurons. The primary triggers for motor neuron degeneration are unknown but inflammation, oxidative stress and mitochondrial defects have been identified as potential contributing factors. Metformin is an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial biogenesis and has been shown to attenuate pathology in mouse models of Huntington's disease and multiple sclerosis. We therefore hypothesized that it might increase survival in the SOD1(G93A) murine model of ALS. Methodology/Principal Findings: Treatment of male and female SOD1(G93A) mice (n = >= 6 per sex) with 2 mg/ml metformin in the drinking water from 35 days, resulted in a significant increase in motor unit survival, as measured by in vivo electrophysiology at 100 days, in male EDL muscles (24+/-2 vs. 14+/-2 motor units, p<0.005) and female TA muscles (21+/-1 vs. 15+/-2 motor units, P = 0.0134). We therefore continued to test the effect of 0.5, 2 and 5 mg/ml metformin in the drinking water from 35 days on disease onset and progression (identified by twice weekly determination of weight and neurological score) as well as survival in male and female SOD1(G93A) mice (n = >= 14 per sex). Results for all groups were compared using Kaplan-Meier time to event analyses. In this survival study, metformin was unable to reduce pathology at any dose and had an unexpected dose-dependent negative effect on the onset of neurological symptoms (P = 0.0236) and on disease progression (P = 0.0362) in female mice. Conclusions/Significance: This study suggests that metformin is a poor candidate for clinical trial in ALS patients and that the possibility of harmful effects of metformin in female ALS patients with type II diabetes should be investigated.
引用
收藏
页数:11
相关论文
共 46 条
[1]   Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS [J].
Alexander, GM ;
Erwin, KL ;
Byers, N ;
Deitch, JS ;
Augelli, BJ ;
Blankenhorn, EP ;
Heiman-Patterson, TD .
MOLECULAR BRAIN RESEARCH, 2004, 130 (1-2) :7-15
[2]   VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model [J].
Azzouz, M ;
Ralph, GS ;
Storkebaum, E ;
Walmsley, LE ;
Mitrophanous, KA ;
Kingsman, SM ;
Carmeliet, P ;
Mazarakis, ND .
NATURE, 2004, 429 (6990) :413-417
[3]   Experimental therapeutics in transgenic mouse models of Huntington's disease [J].
Beal, MF ;
Ferrante, RJ .
NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) :373-384
[4]   Thiazolidinediones, like metformin, inhibit respiratory complex I -: A common mechanism contributing to their antidiabetic actions? [J].
Brunmair, B ;
Staniek, K ;
Gras, F ;
Scharf, N ;
Althaym, A ;
Clara, R ;
Roden, M ;
Gnaiger, E ;
Nohl, H ;
Waldhäusl, W ;
Fürnsinn, C .
DIABETES, 2004, 53 (04) :1052-1059
[5]   Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription [J].
Chen, Yaomin ;
Zhou, Kun ;
Wang, Ruishan ;
Liu, Yun ;
Kwak, Young-Don ;
Ma, Tao ;
Thompson, Robert C. ;
Zhao, Yongbo ;
Smith, Layton ;
Gasparini, Laura ;
Luo, Zhijun ;
Xu, Huaxi ;
Liao, Francesca-Fang .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (10) :3907-3912
[6]  
CHENGYUN Z, 2004, ANN NEUROL, V56, P564
[7]   New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser [J].
Cho, Y. M. ;
Kieffer, T. J. .
DIABETOLOGIA, 2011, 54 (02) :219-222
[8]   Effects of estrogen on lifespan and motor functions in female hSOD1 G93A transgenic mice [J].
Choi, Chan-Il ;
Lee, Young-Don ;
Gwag, Byoung Joo ;
Cho, Sung Ig ;
Kim, Sung-Soo ;
Suh-Kim, Haeyoung .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 268 (1-2) :40-47
[9]   Amyotrophic lateral sclerosis:: From current developments in the laboratory to clinical implications [J].
Cozzolino, Mauro ;
Ferri, Alberto ;
Carri, Maria Teresa .
ANTIOXIDANTS & REDOX SIGNALING, 2008, 10 (03) :405-443
[10]   The "Dying-Back" Phenomenon of Motor Neurons in ALS [J].
Dadon-Nachum, Michal ;
Melamed, Eldad ;
Offen, Daniel .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 43 (03) :470-477